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To assess the usefulness of using cutaneous swabs 
to detect Merkel cell polyomavirus (MCPyV) DNA, we 
analyzed swabs from persons with Merkel cell carcinoma 
(MCC), others with skin diseases, and healthy volunteers. 
MCPyV was detected in at least 1 sample from virtually all 
participants. Viral loads were higher in samples from pa-
tients with MCC.
M
erkel cell polyomavirus (MCPyV) is a recently iden-
tiﬁ  ed human virus initially discovered in tumor tis-
sues of patients with Merkel cell carcinoma (MCC), a rare 
but aggressive skin cancer (1). Several studies have con-
ﬁ  rmed that MCPyV DNA is present in 70%–80% of MCC 
tumors (1–4) and that tumoral cells in most patients show 
a monoclonal integration of the viral genome and expres-
sion of the large T antigen (1,5–7). Furthermore, the inte-
grated viral genome may harbor mutations in the T-antigen 
coding sequence, resulting in truncation of the correspond-
ing helicase protein (8). These data support a causal role 
of MCPyV in tumorogenesis. However, the tumorogenic 
potential of MCPyV remains unclear because the MCPyV 
genome cannot be detected in 20%–30% of MCC tumors, 
whereas MCPyV DNA has been consistently identiﬁ  ed in 
persons with other disorders or in the skin of healthy per-
sons (9–12).
Most studies of MCPyV DNA detection in skin sam-
ples have been performed on biopsy samples. We assessed 
the relevance of using cutaneous swabbing instead of full-
skin tissue samples for viral MCPyV DNA detection. Over-
all, our results show that MCPyV DNA was detected in 
cutaneous swabs from almost all study participants, which 
indicated that MCPyV is likely a ubiquitous virus.
The Study
Cutaneous swabs were obtained from 46 persons: 5 pa-
tients with MCC (median age 76 years, range 68–78 years); 
16 patients with various skin diseases (median age 76.5 
years, range 41–90 years); and 25 clinically healthy volun-
teers (median age 35 years, range 22–58 years) who were 
recruited from among Montpellier University Hospital staff 
(Table). All study participants gave written informed con-
sent, and the study was approved by the local ethics com-
mittee. Cutaneous swabs were collected from the face and, 
for most study participants, from the trunk (chest, back, or 
abdomen) and upper and lower limbs. Lesions in patients 
with MCC or other cutaneous disorders were also swabbed. 
Additionally, buccal mucosa swabs were obtained from 42 
patients.
Swabs were suspended in 400 μL of phosphate-buff-
ered saline, and DNA was extracted from 300 μL of the 
suspension with an automatic EasyMag apparatus (bio-
Mérieux, Marcy l’Etoile, France). The elution volume was 
50 μL, and 10 μL of eluate was used for subsequent PCRs. 
An unused swab, processed in the same way as the cutane-
ous swab, was included in each run as the negative con-
trol. MCPyV DNA was detected by PCR by using large T 
antigen (LT3) and viral capsid protein (VP1) primers (1); 
MCPyV DNA levels were measured by real-time PCR as 
described (11). Total DNA level in swabs was measured 
by using the LightCycler Control DNA Kit (Roche Diag-
nostics, Meylan, France), and results were expressed as 
MCPyV DNA copies/ng DNA.
We analyzed categorical data by using the χ2 test. Con-
tinuous variables were compared by using  the Kruskal-
Wallis test for multiple groups and the Fligner-Policello 
rank tests for pairwise comparisons. Bonferroni correction 
was applied when appropriate. A p value <0.05 was con-
sidered signiﬁ  cant.
Overall, MCPyV DNA was detected in at least 1 swab 
from all but 2 study participants (1 patient with Kaposi 
sarcoma and another with a leg ulcer). MCPyV DNA was 
detected in 141 (79.6%) of 177 cutaneous swabs and in 2 
(4.8%) of 42 buccal mucosa swabs (p<0.001) (Table). The 
viral genome was detected in 27 (93.1%) of 29 cutaneous 
swabs from patients with MCC, in 58 (74.3 %) of 78 from 
patients with other cutaneous diseases, and in 56 (80.0%) 
of 70 from clinically healthy volunteers (p = 0.10). MCPyV 
DNA was more frequently detected on swabs taken from 
the face (43/47, 91.5%) than from the trunk (40/47, 85.1%) 
or limbs (48/69, 69.6%), but the difference was signiﬁ  cant 
only between face and limb swabs (p = 0.005). The MCPyV 
genome was absent from swabs taken from 3 leg ulcers.
Levels of total human DNA were signiﬁ  cantly higher 
in buccal mucosa swabs than in cutaneous swabs (2,170 
pg/μL vs. 62 pg/μL; p<0.001). MCPyV DNA levels were 
higher in cutaneous swabs obtained from patients with 
MCC (median 861 copies/ng DNA) than in those from pa-
tients with other skin diseases (median 45 copies/ng DNA; 
p<0.001) or from the clinically healthy volunteers (medi-
an 43 copies/ng DNA; p<0.001) (Figure). MCPyV DNA 
levels were 5 and 11 copies/ng of DNA in each of the 2 
positive buccal swabs.
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Our results demonstrate that MCPyV DNA can be efﬁ  -
ciently detected by cutaneous swabbing. This easy method 
could be a useful tool for future epidemiologic or molecular 
studies targeting MCPyV. Indeed, this noninvasive proce-
dure may be easily performed without the potential risk for 
side effects related to biopsy collection and is more accept-
able than a biopsy for patients who do not have cutaneous 
disease. The high prevalence of MCPyV DNA at the skin 
surface, contrasted with its low prevalence in buccal mu-
cosa and its absence in skin ulcers (where the epidermis is 
absent), strongly suggests that MCPyV is localized in the 
epidermis. As an alternative hypothesis, MCPyV could be 
released onto the skin surface through sebaceous or sudoral 
secretions. The relative high levels of viral DNA contrast-
ed with the low amount of total DNA in cutaneous swabs 
might indeed support this hypothesis.
A lower prevalence of MCPyV DNA in skin biopsy 
samples among a similar subset of patients has been re-
ported (11). However, this ﬁ  nding may be explained by the 
more limited amounts of superﬁ  cial skin layers in skin bi-
opsy samples compared with those in cutaneous swabs. Be-
cause disinfection of the skin before a biopsy may eliminate 
potential viral DNA from the epidermis, cutaneous swab-
bing may produce a more thorough sample for testing. 
Our results are in accordance with those from a study 
by Loyo et al. that showed widespread distribution of 
MCPyV (12) and with those from a study by Wieland et 
al., who detected MCPyV DNA on the forehead skin of 
62% of healthy persons (13). These ﬁ  ndings strongly sug-
gest that MCPyV is likely present in the skin of almost all 
adults. Furthermore, another recent study on MCPyV sero-
prevalence concluded that MCPyV circulates widely in the 
human population because speciﬁ  c MCPyV antibodies can 
be detected in as much as 80% of persons tested (14). Our 
results indeed support these serologic data and would be 
indicative of a persistent, although asymptomatic, infection 
with MCPyV in the epidermis of most persons.
Our results concur with those of other studies that 
found higher levels of MCPyV DNA in samples from 
MCC patients than from other subsets of patients (11,12). 
Similarly, higher MCPyV-speciﬁ  c antibody titers in pa-
tients with MCC have been reported (14). These consistent 
data suggest that MCPyV is likely involved in MCC path-
omechanisms. However, high MCPyV DNA levels and 
high antibody titers (11,12,14) may be found in persons 
without MCC. The clinical relevance of increased viral 
load or antibody titers, therefore, remains unclear.
Our detection of MCPyV DNA in 2 buccal mucosa 
swabs is in line with recent reports of the widespread vi-
ral DNA in the human body (12,13,15). Even though these 
data might point toward a mucosal, respiratory, or fecal–
oral route of transmission, the skin carriage we observed 
suggests that a cutaneous route should also be considered. 
Cutaneous swabbing could be an effective, less invasive 
method of detecting MCPyV DNA, providing a useful tool 
for future epidemiologic and molecular studies.
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Table. Merkel cell polyomavirus DNA detection rates in swabs  
Swab type 
Patients with MCC* 
(no. positive/no. tested) 
Patients with other skin diseases† 
(no. positive/no. tested) 
Clinically healthy volunteers  
(no. positive/no. tested) 
Buccal mucosa   1/5  0/13 1/24
Cutaneous
 Overall  27/29  58/78  56/70 
 Face  6/6 14/16  23/25 
 Trunk    11/11  16/20  13/16 
 Upper  limb  1//2 10/15  9/14
 Lower  limb  7/8 10/15  11/15 
 Lesion  2/2 8/12 Not  applicable 
*MCC, Merkel cell carcinoma. 
†Patients with Kaposi sarcoma (n = 6), cutaneous drug side-effect (n = 3), leg ulcer (n = 3), bullous pemphigoid (n = 2), psoriasis (n = 1), and mycosis 
fungoides (n = 1). 
Figure. Comparison of Merkel cell polyomavirus DNA levels in 
cutaneous swabs obtained from 46 study participants. A) Patients 
with Merkel cell carcinoma; B) patients with other skin diseases; 
C) clinically healthy volunteers. Data are presented as box-and-
whisker plots. Boxes represent the interquartile range, lines within 
the boxes represent the median value, and whiskers represent 
1.5 × the interquartile range.Merkel Cell Polyomavirus in Cutaneous Swabs
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